Reporting owner · Q3 2026 · CIK 1055951

Orbimed Advisors LLC: insider trades.

Orbimed Advisors LLC reported 27 non-derivative transactions on 13 SEC ownership filings in Q3 2026: 9 open-market purchases ($96.1M) and 2 sales ($9.1M), across 6 companies.

Transactions
27
Purchases (P)
9
Sales (S)
2
Companies
6
Name as filed
ORBIMED ADVISORS LLC

Companies

CompanyRelationshipTransactions
ADARx Pharmaceuticals, Inc. (ADRX)Director, TenPercentOwner11
Electra Therapeutics, Inc. (ETRA)Director, TenPercentOwner6
BlossomHill Therapeutics, Inc. (BLSM)Director3
Braveheart Bio, Inc. (BRVE)Director, TenPercentOwner3
Scribe Therapeutics, Inc. (SCTX)Director2
Sionna Therapeutics, Inc. (SION)Director2

Transactions

27 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-28ADARx Pharmaceuticals, Inc.C564,187—14,025,280Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P300,249$1714,325,529Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C7,127,019—7,127,019Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C1,333,975—8,460,994Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C513,067—8,974,061Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C256,448—9,230,509Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C769,601—13,461,093Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C2,000,962—12,691,492Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C10,690,530—10,690,530Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P61,516$179,292,025Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P588,235$17588,235Form 4
2026-09-21Electra Therapeutics, Inc.C2,002,310—2,002,310Form 4
2026-09-21Electra Therapeutics, Inc.C1,703,314—4,793,558Form 4
2026-09-21Electra Therapeutics, Inc.C758,279—758,279Form 4
2026-09-21Electra Therapeutics, Inc.P1,000,000$151,758,279Form 4
2026-09-21Electra Therapeutics, Inc.C1,087,934—3,090,244Form 4
2026-09-21Electra Therapeutics, Inc.P333,333$155,126,891Form 4
2026-08-10BlossomHill Therapeutics, Inc.C1,039,996—1,039,996Form 4
2026-08-10BlossomHill Therapeutics, Inc.C1,049,283—2,089,279Form 4
2026-08-10BlossomHill Therapeutics, Inc.P625,000$162,714,279Form 4
2026-08-07Braveheart Bio, Inc.P1,666,667$1811,901,826Form 4
2026-08-07Braveheart Bio, Inc.C9,132,420—10,235,159Form 4
2026-08-07Braveheart Bio, Inc.P273,333$18273,333Form 4
2026-07-27Scribe Therapeutics, Inc.P1,000,000$151,348,825Form 4
2026-07-27Scribe Therapeutics, Inc.C348,825—348,825Form 4
2026-07-07Sionna Therapeutics, Inc.S85,918$44.862,469,959Form 4
2026-06-30Sionna Therapeutics, Inc.S115,844$45.52,555,877Form 4

Questions

What stock did Orbimed Advisors LLC buy or sell?

Orbimed Advisors LLC reported 27 non-derivative transactions on 13 SEC ownership filings in Q3 2026: 9 open-market purchases ($96.1M) and 2 sales ($9.1M), across 6 companies.

Is Orbimed Advisors LLC the same person as other filers with this name?

This page covers SEC CIK 1055951 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/orbimed-advisors-llc-1055951.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.